Douglas Forsyth
CIK: 0001240801
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Inhibrx Biosciences, Inc.
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Sep 8, 2026INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect2.5K shares at avg. $114.65$287K - Jun 3, 2026INBX
Inhibrx Biosciences, Inc.
Award(A)DirectStock Option (right to buy)
10K shares- - May 28, 2025INBX
Inhibrx Biosciences, Inc.
Award(A)DirectStock Option (right to buy)
15K shares-
1-3 of 3 transactions
About FORSYTH DOUGLAS
FORSYTH DOUGLAS (SEC CIK 0001240801) files insider reports with the SEC as Director of Inhibrx Biosciences, Inc. (INBX).
Signal8 holds 4 ownership filings by FORSYTH DOUGLAS, all Form 4s, filed between May 29, 2025 and Sep 18, 2026. Those filings report 3 transactions, from May 28, 2025 to Sep 8, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on FORSYTH DOUGLAS's filings is in LA JOLLA, CA.
Recent filings by FORSYTH DOUGLAS
Other insiders filing for Inhibrx Biosciences, Inc. (INBX)
- Lappe Mark, Chief Executive Officer
- Kayyem Jon Faiz, Director
- Vuori Kristiina MD, Director
- MANHARD KIMBERLY, Director
- Matly David, President
- VIKING GLOBAL INVESTORS LP, 10% Owner